50,000 + Uses of the Syn-One Test® Mark Major Diagnostic Milestone
Scottsdale, AZ — November 6, 2025 : CND Life Sciences (CND) announced the completion of its 50,000th Syn-One Test®,...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Scottsdale, AZ — November 6, 2025 : CND Life Sciences (CND) announced the completion of its 50,000th Syn-One Test®,...
Framingham, Massachusetts & Salisbury, England — November 6, 2025 : KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) presented new data at...
BOSTON – October 14, 2025 – BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Astria Therapeutics, Inc. (NASDAQ: ATXS) announced a...
